L'Oréal announces that it has signed an agreement to acquire a majority stake in the British skincare brand Medik8. Inflexion, a European private equity firm, will retain a minority stake. The founder will continue to serve on the board of directors, and the current management team will also remain in place.

Founded by Elliot Isaacs, Medik8 is known for its Crystal Retinal serum and its patented CSA Philosophy(c) method. The brand offers high-end, science-based skincare products and an omnichannel strategy combining clinics, online sales and selective distribution. The company is now available in Europe's leading selective retail outlets and is growing rapidly in the United States.

Medik8 will complement L'Oréal Luxe's portfolio with strong global growth potential. With a range of premium skincare products combining high efficacy and accessible price points, Medik8 perfectly complements our existing skincare portfolio, said Cyril Chapuy, President of L'Oréal Luxe.

Simon Coble, CEO of Medik8, welcomes a shared vision for the brand's future growth and its focus on science and innovation: I look forward to the next stage of the Medik8 journey and working together to bring our innovative products to a wider audience.

L'Oréal will consolidate Medik8's sales upon completion of the transaction, which is expected in the coming months following regulatory approvals. The agreement also includes a right to purchase all shares held by minority shareholders.


Copyright (c) 2025 CercleFinance.com. All rights reserved.